Cevec Introduces CMO Services for the cGMP Manufacturing of CAP Based Clinical Materials

Cevec Pharmaceuticals has extended its CAP Technology Business portfolio by offering cGMP-compliant contract manufacturing services. CAP-derived clinical materials comprising recombinant proteins, vaccines and gene therapy vectors are now directly available from Cevec to support Phase I+II clinical studies.

The CAP manufacturing joint venture with Lisbon-based GenIbet operates state-of-the-art cGMP manufacturing capabilities and allows for a one-stop offer for Cevec customers in need of preclinical and clinical development of CAP cell derived materials. First CAP-based clinical material has already been produced by the GenIbet facility.

“Our vision is to become the leading independent player for human cell line-based clinical materials. This is the next step in growing Cevec along the value chain. The contract manufacturing business will be under the leadership of Frank Ubags, who recently joined us as COO. Frank has an impressive track record in the biopharmaceutical sector in establishing and implementing growth strategies” stated Wolfgang Kintzel, CEO at Cevec.